PMID- 38400148
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20240227
IS  - 2076-393X (Print)
IS  - 2076-393X (Electronic)
IS  - 2076-393X (Linking)
VI  - 12
IP  - 2
DP  - 2024 Feb 6
TI  - Dendritic Cells as a Therapeutic Strategy in Acute Myeloid Leukemia: Vaccines.
LID - 10.3390/vaccines12020165 [doi]
LID - 165
AB  - Dendritic cells (DCs) serve as professional antigen-presenting cells (APC) 
      bridging innate and adaptive immunity, playing an essential role in triggering 
      specific cellular and humoral responses against tumor and infectious antigens. 
      Consequently, various DC-based antitumor therapeutic strategies have been 
      developed, particularly vaccines, and have been intensively investigated 
      specifically in the context of acute myeloid leukemia (AML). This hematological 
      malignancy mainly affects the elderly population (those aged over 65), which 
      usually presents a high rate of therapeutic failure and an unfavorable prognosis. 
      In this review, we examine the current state of development and progress of 
      vaccines in AML. The findings evidence the possible administration of DC-based 
      vaccines as an adjuvant treatment in AML following initial therapy. Furthermore, 
      the therapy demonstrates promising outcomes in preventing or delaying tumor 
      relapse and exhibits synergistic effects when combined with other treatments 
      during relapses or disease progression. On the other hand, the remarkable success 
      observed with RNA vaccines for COVID-19, delivered in lipid nanoparticles, has 
      revealed the efficacy and effectiveness of these types of vectors, prompting 
      further exploration and their potential application in AML, as well as other 
      neoplasms, loading them with tumor RNA.
FAU - Palomares, Francisca
AU  - Palomares F
AUID- ORCID: 0000-0001-5591-7877
AD  - Department of Medical Biochemistry and Molecular Biology, and Immunology, School 
      of Medicine, University of Seville, Av. Sanchez Pizjuan s/n, 41009 Seville, 
      Spain.
AD  - Institute of Biomedicine of Seville (IBiS) HUVR/CSIC/University of Seville, Avda. 
      Manuel Siurot s/n, 41013 Seville, Spain.
FAU - Pina, Alejandra
AU  - Pina A
AD  - Department of Medical Biochemistry and Molecular Biology, and Immunology, School 
      of Medicine, University of Seville, Av. Sanchez Pizjuan s/n, 41009 Seville, 
      Spain.
FAU - Dakhaoui, Hala
AU  - Dakhaoui H
AUID- ORCID: 0000-0001-8716-1437
AD  - Department of Medical Biochemistry and Molecular Biology, and Immunology, School 
      of Medicine, University of Seville, Av. Sanchez Pizjuan s/n, 41009 Seville, 
      Spain.
FAU - Leiva-Castro, Camila
AU  - Leiva-Castro C
AD  - Department of Medical Biochemistry and Molecular Biology, and Immunology, School 
      of Medicine, University of Seville, Av. Sanchez Pizjuan s/n, 41009 Seville, 
      Spain.
FAU - Munera-Rodriguez, Ana M
AU  - Munera-Rodriguez AM
AD  - Department of Medical Biochemistry and Molecular Biology, and Immunology, School 
      of Medicine, University of Seville, Av. Sanchez Pizjuan s/n, 41009 Seville, 
      Spain.
FAU - Cejudo-Guillen, Marta
AU  - Cejudo-Guillen M
AD  - Institute of Biomedicine of Seville (IBiS) HUVR/CSIC/University of Seville, Avda. 
      Manuel Siurot s/n, 41013 Seville, Spain.
AD  - Department of Pharmacology, Pediatry, and Radiology, School of Medicine, 
      University of Seville, Av. Sanchez Pizjuan s/n, 41009 Seville, Spain.
FAU - Granados, Beatriz
AU  - Granados B
AD  - Distrito Sanitario de Atencion Primaria Malaga, Sistema Sanitario Publico de 
      Andalucia, 29004 Malaga, Spain.
FAU - Alba, Gonzalo
AU  - Alba G
AUID- ORCID: 0000-0002-6598-2039
AD  - Department of Medical Biochemistry and Molecular Biology, and Immunology, School 
      of Medicine, University of Seville, Av. Sanchez Pizjuan s/n, 41009 Seville, 
      Spain.
FAU - Santa-Maria, Consuelo
AU  - Santa-Maria C
AUID- ORCID: 0000-0001-9195-2792
AD  - Department of Biochemistry and Molecular Biology, School of Pharmacy, University 
      of Seville, 41012 Seville, Spain.
FAU - Sobrino, Francisco
AU  - Sobrino F
AD  - Department of Medical Biochemistry and Molecular Biology, and Immunology, School 
      of Medicine, University of Seville, Av. Sanchez Pizjuan s/n, 41009 Seville, 
      Spain.
FAU - Lopez-Enriquez, Soledad
AU  - Lopez-Enriquez S
AUID- ORCID: 0000-0003-3727-1843
AD  - Department of Medical Biochemistry and Molecular Biology, and Immunology, School 
      of Medicine, University of Seville, Av. Sanchez Pizjuan s/n, 41009 Seville, 
      Spain.
AD  - Institute of Biomedicine of Seville (IBiS) HUVR/CSIC/University of Seville, Avda. 
      Manuel Siurot s/n, 41013 Seville, Spain.
LA  - eng
GR  - Project-202200000421/Universidad de Sevilla/
GR  - Project-2023/00000482/Universidad de Sevilla/
GR  - RYC2021-031256-I/Ministerio de Ciencia e Innovacion/
PT  - Journal Article
PT  - Review
DEP - 20240206
PL  - Switzerland
TA  - Vaccines (Basel)
JT  - Vaccines
JID - 101629355
PMC - PMC10891551
OTO - NOTNLM
OT  - COVID-19
OT  - dendritic cells
OT  - immunotherapy
OT  - mRNA
OT  - personalized medicine
OT  - vaccines
COIS- The authors declare no conflicts of interest.
EDAT- 2024/02/24 11:46
MHDA- 2024/02/24 11:47
PMCR- 2024/02/06
CRDT- 2024/02/24 01:23
PHST- 2023/12/16 00:00 [received]
PHST- 2024/01/11 00:00 [revised]
PHST- 2024/02/04 00:00 [accepted]
PHST- 2024/02/24 11:47 [medline]
PHST- 2024/02/24 11:46 [pubmed]
PHST- 2024/02/24 01:23 [entrez]
PHST- 2024/02/06 00:00 [pmc-release]
AID - vaccines12020165 [pii]
AID - vaccines-12-00165 [pii]
AID - 10.3390/vaccines12020165 [doi]
PST - epublish
SO  - Vaccines (Basel). 2024 Feb 6;12(2):165. doi: 10.3390/vaccines12020165.